Cilofexor shows no liver fibrosis benefits for patients with PSC The FXR agonist cilofexor does not slow down fibrosis progression in patients with noncirrhotic primary sclerosing cholangitis.

#MedNews - The FXR agonist #cilofexor does not slow down fibrosis progression in patients with noncirrhotic primary sclerosing #cholangitis.

Full story 👉 buff.ly/LVHpldc

#GastroSky